Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2020 1
2021 4
2022 7
2023 12
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: suelmann bbm. Nat Med. 2023 Mar;29(3):588-592. doi: 10.1038/s41591-022-02199-y. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732628 Clinical Trial.
Hematologic malignancies following immune checkpoint inhibition for solid tumors.
van Eijs MJM, van der Wagen LE, Mous R, Leguit RJ, van de Corput L, van Lindert ASR, Suelmann BBM, Kamphuis AM, Nierkens S, Suijkerbuijk KPM. van Eijs MJM, et al. Among authors: suelmann bbm. Cancer Immunol Immunother. 2023 Jan;72(1):249-255. doi: 10.1007/s00262-022-03230-4. Epub 2022 Jun 13. Cancer Immunol Immunother. 2023. PMID: 35691988 Free PMC article.
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Stockem CF, et al. Among authors: suelmann bbm. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023. Front Oncol. 2023. PMID: 37711193 Free PMC article.
Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy.
Breekveldt ECH, Ykema BLM, Bisseling TM, Moons LMG, Spaander MCW, Huibregtse IL, van der Biessen-van Beek DTJ, Mulder SF, Saveur L, Kerst JM, Zweers D, Suelmann BBM, de Wit R, Reijm A, van Baalen S, Butterly LF, Hisey WM, Robinson CM, van Vuuren AJ, Carvalho B, Lansdorp-Vogelaar I, Schaapveld M, van Leeuwen FE, Snaebjornsson P, van Leerdam ME. Breekveldt ECH, et al. Among authors: suelmann bbm. Int J Cancer. 2024 Apr 15;154(8):1474-1483. doi: 10.1002/ijc.34810. Epub 2023 Dec 27. Int J Cancer. 2024. PMID: 38151749
30 results